Bisphosphonates as adjuvant treatment for breast cancer: Their effects are unclear, and long term trials are needed

British Medical Journal

Volumn 325, Issue 7372, 2002, Pages 1051-1052

  Gralow, Julie R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOKINE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER RECURRENCE; CYTOKINE PRODUCTION; DRUG EFFICACY; EDITORIAL; IMMUNOCYTOCHEMISTRY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL;

ADMINISTRATION, ORAL; ANTIMETABOLITES; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037049019     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000;88:1082-90.
2. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
3. van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:491-8.
4. Body JJ, Lichinitser MR, Diehl I, Schlosser K, Pfarr E, Cavalli F, et al. Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 1999;19:abstract 2222.
5. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
6. Tripathy D, Lazarev A, Lichinitser MR, Decker D, McLachlan SA. Budde M. Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases [abstract 17]. Proc Am Soc Clin Oncol 2002;22.
7. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
8. Diel IJ, Solomayer EF, Gollan C. Bisphosphonates in the reduction of metastases in breast cancer - Extended follow-up results [abstract 314]. Proc Am Soc Clin Oncol 2000.
9. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-7.
10. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A. et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24.
11. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002;(1):CD003474.
12. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of hisphosphonates in breast cancer. J Clin Oncol 2000;18:1378-91.